Unfractionated heparin and low-molecular-weight heparins are commonly used as thromboprophylaxis for hospitalized patients. Though generally considered safe at prophylactic doses, cases of catastrophic hemorrhage have been reported. The proposed mechanism involves bioaccumulation of heparin through saturation of the rapid-elimination pathway in its metabolism. We present an unusual case of an average-weight man with metastatic melanoma who suffered hemorrhage with syncope and end-organ damage while on prophylactic three times daily unfractionated heparin. Coagulation studies were consistent with heparin toxicity. Despite administration of protamine, the clearance of heparin was remarkably delayed, as demonstrated by serial coagulation studies. We review the suspected risk factors for heparin bioaccumulation and the emerging understanding of this unusual adverse event involving a nearly ubiquitous medication.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2CPxARD
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
Abstract Background We have previously published data from 2001 to 2006 showing that adolescent and young adult (AYA) oncology patients ...
-
Abstract Desmoplastic small round cell tumor (DSCRT) is a rare malignancy most often seen in the abdomen or pelvis of young men. Unfortuna...
-
Here is your sample essay on Advertising Advertising is an important element of our culture because it reflects and attempts to change our l...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nGQ2DC via IFTTT
-
Objective To determine the association between neuroendocrine tumor (NET) biomarker levels and the extent of disease as assessed by 68 Ga DO...
-
Abstract Ankylosing spondylitis (AS) is characterized by excessive bone formation with syndesmophytes, leading to bony ankylosis. The cont...
-
by Mindaugas Paužuolis, Torsten Eich, Joachim Burman Background Natalizumab (NTZ) is a drug that has been widely used in the treatment of m...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου